Gronqvist, Erik; Lundin, Douglas - In: Economics of Innovation and New Technology 18 (2009) 5, pp. 513-531
It is often argued that drug companies do not wish to carry out post-approval head-to-head clinical trials, since their drugs may be revealed as being no better than existing drugs. However, we show that standard models for vertical differentiation predicts that pharmaceutical companies would in...